If approved, imlifidase will be the first treatment to address highly sensitized patients awaiting kidney transplantation. LUND, Sweden, March 4, 2026 /PRNewswire/ -- Hansa Biopharma AB, ("Hansa" or "the Company"), (Nasdaq Stockholm: HNSA), today announced that the Food and Drug Administration (FDA) has notified the company that the previously accepted Biologics License Application (BLA) for imlifidase has been assigned a Prescription Drug User Fee Act (PDUFA) action date of December 19, 2026.

CALGARY, AB, March 4, 2026 /PRNewswire/ - Nanalysis Scientific Corp. (the " Company" or " Nanalysis") (TSXV: NSCI) (FRA: 1N1) announces the Company's Board of Directors has granted 1,210,000 restricted share units ("RSUs") and 350,000 stock options ("Options") to certain directors, officers and employees of the Company, pursuant to the Company's stock option plan and restricted share unit plan (the "RSU Plan"), as applicable. Each Option is exercisable, once vested, to purchase one common share

SAN DIEGO, March 4, 2026 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces purchasers or acquirers of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) common stock between August 3, 2023 and December 26, 2025, both dates inclusive (the "Class Period"), have until Monday, April 6, 2026 to seek appointment as lead plaintiff of the Ultragenyx class action lawsuit. Captioned Bailey v. Ultragenyx Pharmaceutical Inc., No. 26-cv-01097 (N.D. Cal.), the Ultragenyx class action lawsuit charges Ultr

CHICAGO, March 4, 2026 /PRNewswire/ -- Ziegler, a specialty investment bank, is pleased to announce that it served as the exclusive financial advisor to Preferred Vascular Group (PVG) in connection with its acquisition by Surgery Partners (NASDAQ: SGRY), a leading operator of surgical facilities and ancillary services. Founded in 2005, PVG is a leading Ambulatory Surgical Center (ASC) operator focused specifically on dialysis access procedures, with eight ASCs in Georgia and Ohio. Don Holton fou

Joining the world’s largest rare disease patient network to support patients across the globe in resource-limited settings and set diagnostic standards. iHope is excited to leverage 3billion’s 75-country global infrastructure to maximize diagnostic impact. We have millions of children and adults waiting for a diagnosis - this is their birthright.” — Sharon Terry, CEO, Genetic Alliance SAN DIEGO, CA, UNITED STATES, March 4, 2026 / EINPresswire.com / -- 3billion (CEO Changwon Kum), a global leader

MADISON, Wis., March 4, 2026 /PRNewswire/ -- BrainXell today announced the launch of its human induced pluripotent stem cell (iPSC)-derived sensory neurons, a scalable human cellular platform engineered to support reproducible functional studies in pain biology, sensory transduction, and ion channel pharmacology. BrainXell sensory neurons demonstrate robust expression of hallmark sensory neuron genes and proteins, including voltage-gated sodium channels Nav1.7, Nav1.8, and Nav1.9, TRP channels T

RBL LLC biotechnology startup SteerBio to drive clinical development and commercialization HOUSTON, March 4, 2026 /PRNewswire/ --A team of researchers led by Rice University bioengineer Omid Veiseh has been awarded $18.2 million in funding from the Advanced Research Projects Agency for Health (ARPA-H) to develop a first-of-its-kind regenerative treatment aimed at restoring damaged lymphatic vessels and potentially curing lymphedema, a condition that affects more than 10 million Americans. The aw

NEW ORLEANS--(BUSINESS WIRE)--A retrospective study by Hospital for Special Surgery (HSS) investigators found that infection rates at a high-volume academic orthopedic center following total knee arthroplasty (TKA) are uniformly low regardless of individual surgeon volume. These findings challenge the long-held belief that a surgeon’s experience, not the institution’s, drives safety outcomes. The research team shared their study results in a presentation at the American Academy of Orthopedic Sur

NEW YORK--(BUSINESS WIRE)--Flo Health, the world's #1 women's health app, today announced the publication of a landmark peer-reviewed study demonstrating that its digital Symptom Checker could reduce the average time to endometriosis diagnosis from approximately seven years to around three years, representing a reduction of more than 50%. The study, published in npj Digital Medicine within the prestigious Nature Portfolio, is the first economic evaluation of a digital symptom checker for endomet

WALTHAM, Mass.--(BUSINESS WIRE)--Arsenal Medical, a clinical-stage company pioneering innovative biomaterials-based devices, today announced the first patient treated with a first-of-its-kind device, ResQFoam™, in the REVIVE clinical study at the University of Alabama at Birmingham (UAB). ResQFoam is an investigational trauma intervention designed to function like a human “fix-a-flat.” When injected into the abdominal cavity, it rapidly expands to apply internal pressure helping slow bleeding in